212 related articles for article (PubMed ID: 36745479)
1. Critical Role of Position 10 Residue in the Polymyxin Antimicrobial Activity.
Patil NA; Ma W; Jiang X; He X; Yu HH; Wickremasinghe H; Wang J; Thompson PE; Velkov T; Roberts KD; Li J
J Med Chem; 2023 Feb; 66(4):2865-2876. PubMed ID: 36745479
[TBL] [Abstract][Full Text] [Related]
2. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria.
Evans ME; Feola DJ; Rapp RP
Ann Pharmacother; 1999 Sep; 33(9):960-7. PubMed ID: 10492501
[TBL] [Abstract][Full Text] [Related]
3. Polymyxin B: similarities to and differences from colistin (polymyxin E).
Kwa A; Kasiakou SK; Tam VH; Falagas ME
Expert Rev Anti Infect Ther; 2007 Oct; 5(5):811-21. PubMed ID: 17914915
[TBL] [Abstract][Full Text] [Related]
4. Polymyxins for CNS infections: Pharmacology and neurotoxicity.
Velkov T; Dai C; Ciccotosto GD; Cappai R; Hoyer D; Li J
Pharmacol Ther; 2018 Jan; 181():85-90. PubMed ID: 28750947
[TBL] [Abstract][Full Text] [Related]
5. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus.
Nation RL; Li J; Cars O; Couet W; Dudley MN; Kaye KS; Mouton JW; Paterson DL; Tam VH; Theuretzbacher U; Tsuji BT; Turnidge JD
Lancet Infect Dis; 2015 Feb; 15(2):225-34. PubMed ID: 25459221
[TBL] [Abstract][Full Text] [Related]
6. Rational use of intravenous polymyxin B and colistin: A review.
Zakuan ZD; Suresh K
Med J Malaysia; 2018 Oct; 73(5):351-359. PubMed ID: 30350826
[TBL] [Abstract][Full Text] [Related]
7. New polymyxin derivatives that display improved efficacy in animal infection models as compared to polymyxin B and colistin.
Vaara M
Med Res Rev; 2018 Sep; 38(5):1661-1673. PubMed ID: 29485690
[TBL] [Abstract][Full Text] [Related]
8. Rescuing the Last-Line Polymyxins: Achievements and Challenges.
Nang SC; Azad MAK; Velkov T; Zhou QT; Li J
Pharmacol Rev; 2021 Apr; 73(2):679-728. PubMed ID: 33627412
[TBL] [Abstract][Full Text] [Related]
9. Causes of polymyxin treatment failure and new derivatives to fill the gap.
Chiu S; Hancock AM; Schofner BW; Sniezek KJ; Soto-Echevarria N; Leon G; Sivaloganathan DM; Wan X; Brynildsen MP
J Antibiot (Tokyo); 2022 Nov; 75(11):593-609. PubMed ID: 36123537
[TBL] [Abstract][Full Text] [Related]
10. A Novel Chemical Biology Approach for Mapping of Polymyxin Lipopeptide Antibody Binding Epitopes.
Velkov T; Yun B; Schneider EK; Azad MA; Dolezal O; Morris FC; Nation RL; Wang J; Chen K; Yu HH; Wang L; Thompson PE; Roberts KD; Li J
ACS Infect Dis; 2016 May; 2(5):341-51. PubMed ID: 27627202
[TBL] [Abstract][Full Text] [Related]
11. Enhancing the antibacterial activity of polymyxins using a nonantibiotic drug.
Krishnamurthy M; Lemmon MM; Falcinelli EM; Sandy RA; Dootz JN; Mott TM; Rajamani S; Schaecher KE; Duplantier AJ; Panchal RG
Infect Drug Resist; 2019; 12():1393-1405. PubMed ID: 31239720
[No Abstract] [Full Text] [Related]
12. History, Chemistry and Antibacterial Spectrum.
Velkov T; Thompson PE; Azad MAK; Roberts KD; Bergen PJ
Adv Exp Med Biol; 2019; 1145():15-36. PubMed ID: 31364069
[TBL] [Abstract][Full Text] [Related]
13. Teaching 'old' polymyxins new tricks: new-generation lipopeptides targeting gram-negative 'superbugs'.
Velkov T; Roberts KD; Nation RL; Wang J; Thompson PE; Li J
ACS Chem Biol; 2014 May; 9(5):1172-7. PubMed ID: 24601489
[TBL] [Abstract][Full Text] [Related]
14. Development of dilipid polymyxins: Investigation on the effect of hydrophobicity through its fatty acyl component.
Domalaon R; Berry L; Tays Q; Zhanel GG; Schweizer F
Bioorg Chem; 2018 Oct; 80():639-648. PubMed ID: 30053708
[TBL] [Abstract][Full Text] [Related]
15. Colistin and polymyxin B in critical care.
Michalopoulos A; Falagas ME
Crit Care Clin; 2008 Apr; 24(2):377-91, x. PubMed ID: 18361952
[TBL] [Abstract][Full Text] [Related]
16. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review.
Zavascki AP; Goldani LZ; Li J; Nation RL
J Antimicrob Chemother; 2007 Dec; 60(6):1206-15. PubMed ID: 17878146
[TBL] [Abstract][Full Text] [Related]
17. Rediscovering the octapeptins.
Velkov T; Roberts KD; Li J
Nat Prod Rep; 2017 Mar; 34(3):295-309. PubMed ID: 28180225
[TBL] [Abstract][Full Text] [Related]
18. Deep Mutational Scanning Reveals the Active-Site Sequence Requirements for the Colistin Antibiotic Resistance Enzyme MCR-1.
Sun Z; Palzkill T
mBio; 2021 Dec; 12(6):e0277621. PubMed ID: 34781730
[TBL] [Abstract][Full Text] [Related]
19. Polymyxin B nonapeptide potentiates the eradication of Gram-negative bacterial persisters.
Kim SJ; Jo J; Kim J; Ko KS; Lee W
Microbiol Spectr; 2024 Apr; 12(4):e0368723. PubMed ID: 38391225
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial Activity and Toxicity of the Major Lipopeptide Components of Polymyxin B and Colistin: Last-line Antibiotics against Multidrug-Resistant Gram-negative Bacteria.
Roberts KD; Azad MA; Wang J; Horne AS; Thompson PE; Nation RL; Velkov T; Li J
ACS Infect Dis; 2015 Nov; 1(11):568-575. PubMed ID: 27525307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
